178 related articles for article (PubMed ID: 24729124)
1. Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance.
Lin CY; Sheu MJ; Li CF; Lee SW; Lin LC; Wang YF; Chen SH
Tumour Biol; 2014 Jul; 35(7):6823-30. PubMed ID: 24729124
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
Lee YY; Li CF; Lin CY; Lee SW; Sheu MJ; Lin LC; Chen TJ; Wu TF; Hsing CH
Tumour Biol; 2014 Nov; 35(11):11097-105. PubMed ID: 25099619
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ANXA1 confers independent negative prognostic impact in rectal cancers receiving concurrent chemoradiotherapy.
Sheu MJ; Li CF; Lin CY; Lee SW; Lin LC; Chen TJ; Ma LJ
Tumour Biol; 2014 Aug; 35(8):7755-63. PubMed ID: 24810927
[TBL] [Abstract][Full Text] [Related]
5. High chloride channel accessory 1 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
Chen TJ; He HL; Shiue YL; Yang CC; Lin LC; Tian YF; Chen SH
Int J Med Sci; 2018; 15(11):1171-1178. PubMed ID: 30123054
[No Abstract] [Full Text] [Related]
6. High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.
Lin CY; Hsieh PL; Chou CL; Yang CC; Lee SW; Tian YF; Shiue YL; Li WS
Oncology; 2020; 98(8):549-557. PubMed ID: 32408308
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy.
Lee YY; Wei YC; Tian YF; Sun DP; Sheu MJ; Yang CC; Lin LC; Lin CY; Hsing CH; Li WS; Li CF; Hsieh PL; Lin CY
J Cancer; 2017; 8(8):1330-1337. PubMed ID: 28638446
[No Abstract] [Full Text] [Related]
8. Overexpression of REG4 confers an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Hsing CH; Huang HY; Wang JY; Li CF
J Surg Oncol; 2014 Dec; 110(8):1002-10. PubMed ID: 25155043
[TBL] [Abstract][Full Text] [Related]
9. The prognostic impact of lipid biosynthesis-associated markers, HSD17B2 and HMGCS2, in rectal cancer treated with neoadjuvant concurrent chemoradiotherapy.
Lee YE; He HL; Shiue YL; Lee SW; Lin LC; Wu TF; Chang IW; Lee HH; Li CF
Tumour Biol; 2015 Sep; 36(10):7675-83. PubMed ID: 25929810
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of DNAJC12 predicts poor response to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
He HL; Lee YE; Chen HP; Hsing CH; Chang IW; Shiue YL; Lee SW; Hsu CT; Lin LC; Wu TF; Li CF
Exp Mol Pathol; 2015 Jun; 98(3):338-45. PubMed ID: 25805104
[TBL] [Abstract][Full Text] [Related]
11. High SPINK4 Expression Predicts Poor Outcomes among Rectal Cancer Patients Receiving CCRT.
Chen TJ; Tian YF; Chou CL; Chan TC; He HL; Li WS; Tsai HH; Li CF; Lai HY
Curr Oncol; 2021 Jun; 28(4):2373-2384. PubMed ID: 34202399
[TBL] [Abstract][Full Text] [Related]
12. SERPINB5 Expression: Association with CCRT Response and Prognostic Value in Rectal Cancer.
Chang IW; Liu KW; Ragunanan M; He HL; Shiue YL; Yu SC
Int J Med Sci; 2018; 15(4):376-384. PubMed ID: 29511373
[No Abstract] [Full Text] [Related]
13. Low BRCA2 expression predicts poor prognoses in patients with rectal cancer receiving chemoradiotherapy.
Sheu MJ; Chou CL; Yang CC; Lee SW; Tian YF; Lin CY; Hsiao SY; Chen SH; Huang WT
Pathol Res Pract; 2020 May; 216(5):152922. PubMed ID: 32249003
[TBL] [Abstract][Full Text] [Related]
14. PLA2G2A overexpression is associated with poor therapeutic response and inferior outcome in rectal cancer patients receiving neoadjuvant concurrent chemoradiotherapy.
He HL; Lee YE; Shiue YL; Lee SW; Lin LC; Chen TJ; Wu TF; Li CF
Histopathology; 2015 Jun; 66(7):991-1002. PubMed ID: 25393083
[TBL] [Abstract][Full Text] [Related]
15. High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT.
Chen HP; Chen CI; Liu KW; Chen TJ; Tian YF; Kuo YH; Li WS; Tsai HH; Wu LC; Yeh CF; Li CF; Chou CL; Lai HY
Pathol Res Pract; 2022 Nov; 239():154158. PubMed ID: 36244249
[TBL] [Abstract][Full Text] [Related]
16. DPYD, TYMS, TYMP, TK1, and TK2 genetic expressions as response markers in locally advanced rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy.
Huang MY; Wu CH; Huang CM; Chung FY; Huang CW; Tsai HL; Chen CF; Lin SR; Wang JY
Biomed Res Int; 2013; 2013():931028. PubMed ID: 24455740
[TBL] [Abstract][Full Text] [Related]
17. Role of autophagy-related protein expression in patients with rectal cancer treated with neoadjuvant chemoradiotherapy.
Shim BY; Sun S; Won HS; Lee MA; Hong SU; Jung JH; Cho HM; Ko YH
BMC Cancer; 2016 Mar; 16():207. PubMed ID: 26965179
[TBL] [Abstract][Full Text] [Related]
18. REG3A overexpression functions as a negative predictive and prognostic biomarker in rectal cancer patients receiving CCRT.
Li WS; Chen TJ; Lee SW; Yang CC; Tian YF; Kuo YH; Tsai HH; Wu LC; Yeh CF; Shiue YL; Chou CL; Lai HY
Histol Histopathol; 2024 Jan; 39(1):91-104. PubMed ID: 37042618
[TBL] [Abstract][Full Text] [Related]
19. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma.
Zhang B; Dong LW; Tan YX; Zhang J; Pan YF; Yang C; Li MH; Ding ZW; Liu LJ; Jiang TY; Yang JH; Wang HY
Br J Cancer; 2013 Jul; 109(1):14-23. PubMed ID: 23764751
[TBL] [Abstract][Full Text] [Related]
20. BMI1-KLF4 axis deficiency improves responses to neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Hsu YC; Luo CW; Huang WL; Wu CC; Chou CL; Chen CI; Chang SJ; Chai CY; Wang HC; Chen TY; Li CF; Pan MR
Radiother Oncol; 2020 Aug; 149():249-258. PubMed ID: 32592893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
